Please ensure Javascript is enabled for purposes of website accessibility

Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today

By Todd Campbell – Jul 1, 2020 at 3:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer released intriguing data regarding its own COVID-19 vaccine.

What happened

Dynavax (DVAX 0.83%) shares were trading 6.5% lower as of 3:35 p.m. EDT on Wednesday after competitor Pfizer (PFE 0.42%) reported data showing its vaccine produces a significantly larger number of antibodies than are found in recovered COVID-19 patients.

So what

Dynavax is collaborating with a number of companies on the development of a COVID-19 vaccine, but trials involving the adjuvant it's contributing to boost immune responses in these collaborations have only just begun, suggesting other players, including Pfizer, may reach the market sooner.

A person speaking through a megaphone.

Image source: Getty Images.

On Wednesday, Pfizer and its partner, BioNTech (BNTX 0.90%), announced one vaccine candidate it's evaluating in a small phase 1/2 trial resulted in neutralizing antibody levels that were up to 2.8 times higher than levels seen in recovered COVID-19 patients. The news suggests Pfizer could to deliver on its goal of advancing at least one vaccine into a large, phase 2b/3 clinical trial as early as next month.

Since Pfizer's success suggests it may be further ahead of Dynavax in the race to launching an FDA-approved vaccine, Dynavax's potential market opportunity could wind up being smaller than previously anticipated.

Now what

A number of healthcare companies are in various stages of COVID-19 vaccine development, including Moderna, which is already in phase 2 studies for its mRNA vaccine candidate.

It's too early to say what vaccine will become available first, or which vaccine candidate will work best. A phase 1 trial by one of Dynavax's collaborators, Clover Biopharmaceuticals, recently began enrolling patients, so investors might not want to count the company out yet. If evidence emerges that one of the vaccines incorporating Dynavax's technology produces neutralizing antibodies at a similar or higher level than Pfizer's, it could eventually see its shares rebound.

 

Todd Campbell owns shares of Pfizer. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$10.90 (0.83%) $0.09
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.33 (0.42%) $0.18
BioNTech SE Stock Quote
BioNTech SE
BNTX
$137.91 (0.90%) $1.23
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$125.83 (4.00%) $4.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.